Vaccine proves to be efficient in treating prostate cancer

At the prostate cancer symposium in Orlando,placebo treatment, the overall of survival was 21.4
co-sponsored by the American Society of Clinicalmonths.
Oncology, Eric J. Small, MD, UCSF professor ofThe conclusions were that 115 patients of this group
medicine and urology presented the findings of thehad progressive disease at the time of data analysis
study he led helped by other 19 US institutions,and all patients were followed for survival for 3
regarding an effective treatment for prostate cancer.years.
Scientists said that the rate of survival increased byScientists do not know if the vaccine will work on
four and a half months in those who werepatients suffering of early-stage prostate cancer and
administered the cancer vaccine compared withof explosive terminal cancer. The vaccine, called
those who got the placebo.Provenge, does not cure cancer but at least it slows
For the patients this is great news because it givesit down.
them hope that an even better vaccine could beOther cancer vaccines are being developed for
discovered. This vaccine is not like the others thattreating: leukemia, breast cancer, colon cancer, and
are designed to prevent a disease. This is made tokidney and pancreas cancer as well.
treat advanced prostate cancer by increasing theThe human body is not able to recognize the cancer
immune system's response to cancer cells.cells and that is why it can not fight them without
The vaccine was well tolerated by patients and thehelp. The vaccine is designed to alert the body is
side effects were mild: fever and chills. This is goodcancerous cells are present. Provenge has been made
news because chemotherapy and radiation gives a lotout of a genetically engineered protein and a dendritic
of unbearable side effects.cell provided from the patient's bloodstream. After
Small included in the study 127 patients suffering ofgetting the vaccine shots, the immune system will
asymptomatic metastatic hormone refractoryreact and will activate immune T-cells to find and
prostate cancer (HRPC). 82 of them received thedestroy the cancer cells.
vaccine and 45 got placebo. They were administeredThis discovery is important not only for those who
three shots over six weeks. The treatmentsuffer of the disease but also for the field. This
continued three years.vaccine confirms what everybody denied, that
For those treated with the vaccine, the median ratevaccines can really work.
of survival was 25.9 months. For those who got a